Do analysts prefer PPBT or XTLB?

Purple Biotech presently has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher possible upside, equities analysts plainly believe Purple Biotech is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PPBT or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -147.77% -111.59% XTL Biopharmaceuticals N/A N/A N/A

Do analysts rate CDIO or PPBT?

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate PPBT or PMCB?

Purple Biotech currently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Purple Biotech is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PPBT or PMCB?

Nuvilex is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$23.25 N/A Nuvilex N/A N/A -$19.42M -$3.00 N/A

Is PPBT or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -147.77% -111.59% Nuvilex N/A 0.25% 0.18%

Is BCAB or PPBT more profitable?

BioAtla's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% Purple Biotech N/A -147.77% -111.59%

Do analysts rate PPBT or BRTX?

Purple Biotech presently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Purple Biotech is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Purple Biotech (PPBT) Competitors

$1.70 +0.02 (+1.19%)

As of 09:32 AM Eastern

Compare

PPBT vs. XTLB, CDIO, PMCB, BCAB, and BRTX

Should you buy Purple Biotech stock or one of its competitors? Purple Biotech's main competitors and comparable companies include XTL Biopharmaceuticals (XTLB), Cardio Diagnostics (CDIO), Nuvilex (PMCB), BioAtla (BCAB), and Biorestorative Therapies (BRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Purple Biotech compare to XTL Biopharmaceuticals?

Purple Biotech (NASDAQ:PPBT) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Purple Biotech has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

XTL Biopharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
XTL Biopharmaceuticals	N/A	N/A	N/A

Purple Biotech presently has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher possible upside, equities analysts plainly believe Purple Biotech is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals has higher revenue and earnings than Purple Biotech. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
XTL Biopharmaceuticals	$450K	12.08	-$6.97M	-$0.64	N/A

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Purple Biotech's score of 0.44 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
XTL Biopharmaceuticals	Positive

Summary

XTL Biopharmaceuticals beats Purple Biotech on 8 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Purple Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Purple Biotech	N/A	-147.77%	-111.59%

Cardio Diagnostics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than Purple Biotech. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$14.45K	378.96	-$6.50M	-$2.92	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 2 articles in the media. Cardio Diagnostics' average media sentiment score of 1.25 beat Purple Biotech's score of 0.44 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Positive
Purple Biotech	Neutral

Summary

Cardio Diagnostics beats Purple Biotech on 8 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to Nuvilex?

Purple Biotech (NASDAQ:PPBT) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Purple Biotech has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Purple Biotech currently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Purple Biotech is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex's return on equity of 0.25% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
Nuvilex	N/A	0.25%	0.18%

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Purple Biotech had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.87 beat Purple Biotech's score of 0.44 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
Nuvilex	Very Positive

Nuvilex is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

Summary

Nuvilex beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

In the previous week, Purple Biotech had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.89 beat Purple Biotech's score of 0.44 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Purple Biotech	Neutral

BioAtla presently has a consensus target price of $200.00, indicating a potential upside of 11,394.25%. Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,685.71%. Given BioAtla's higher possible upside, equities research analysts clearly believe BioAtla is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Purple Biotech	N/A	-147.77%	-111.59%

BioAtla has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Purple Biotech has lower revenue, but higher earnings than BioAtla. Purple Biotech is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	1.45	-$59.61M	-$25.45	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BioAtla beats Purple Biotech on 8 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to Biorestorative Therapies?

Purple Biotech (NASDAQ:PPBT) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Biorestorative Therapies has higher revenue and earnings than Purple Biotech. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
Biorestorative Therapies	$360K	14.09	-$14.24M	-$1.07	N/A

Purple Biotech presently has a consensus price target of $30.00, suggesting a potential upside of 1,685.71%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Purple Biotech is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Purple Biotech has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Purple Biotech has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Purple Biotech's return on equity of -147.77% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. Biorestorative Therapies' average media sentiment score of 1.44 beat Purple Biotech's score of 0.44 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
Biorestorative Therapies	Positive

Summary

Purple Biotech and Biorestorative Therapies tied by winning 7 of the 14 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.56M	$3.94B	$7.18B	$12.88B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.07	11.68	273.17	25.44
Price / Sales	N/A	1,401.93	637.42	103.51
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.16	16.92	11.08	6.36
Net Income	-$26.39M	-$22.74M	$3.48B	$349.79M
7 Day Performance	7.35%	-0.13%	0.21%	-0.48%
1 Month Performance	20.00%	11.45%	7.75%	4.17%
1 Year Performance	-91.56%	55.66%	24.68%	15.11%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	2.1596 of 5 stars	$1.70 +1.2%	$30.00 +1,664.7%	-91.6%	$1.58M	N/A	N/A	20	Short Interest Increase Gap Up
XTLB XTL Biopharmaceuticals	0.9745 of 5 stars	$2.60 -1.1%	N/A	N/A	$5.78M	$450K	N/A	N/A	Positive News Short Interest Decrease
CDIO Cardio Diagnostics	0.7239 of 5 stars	$1.91 -0.8%	N/A	-52.2%	$5.70M	$10K	N/A	1	Positive News
PMCB Nuvilex	1.4407 of 5 stars	$0.54 +2.8%	N/A	-45.2%	$5.64M	N/A	N/A	4	Positive News
BCAB BioAtla	1.9108 of 5 stars	$3.26 -0.6%	$200.00 +6,035.0%	-92.4%	$5.46M	$2M	N/A	60	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. XTLB, CDIO, PMCB, BCAB, and BRTX

How does Purple Biotech compare to XTL Biopharmaceuticals?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Summary

How does Purple Biotech compare to Nuvilex?

Summary

How does Purple Biotech compare to BioAtla?

Summary

How does Purple Biotech compare to Biorestorative Therapies?

Summary

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. XTLB, CDIO, PMCB, BCAB, and BRTX

How does Purple Biotech compare to XTL Biopharmaceuticals?

Which has more volatility & risk, PPBT or XTLB?

Is PPBT or XTLB more profitable?

Do analysts prefer PPBT or XTLB?

Which has higher earnings & valuation, PPBT or XTLB?

Do institutionals and insiders believe in PPBT or XTLB?

Does the media refer more to PPBT or XTLB?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Do analysts rate CDIO or PPBT?

Do insiders and institutionals have more ownership in CDIO or PPBT?

Is CDIO or PPBT more profitable?

Which has more risk and volatility, CDIO or PPBT?

Which has preferable valuation and earnings, CDIO or PPBT?

Does the media prefer CDIO or PPBT?

Summary

How does Purple Biotech compare to Nuvilex?

Which has more risk and volatility, PPBT or PMCB?

Do analysts rate PPBT or PMCB?

Is PPBT or PMCB more profitable?

Do insiders and institutionals have more ownership in PPBT or PMCB?

Does the media favor PPBT or PMCB?

Which has better valuation & earnings, PPBT or PMCB?

Summary

How does Purple Biotech compare to BioAtla?

Does the media favor BCAB or PPBT?

Do analysts prefer BCAB or PPBT?

Is BCAB or PPBT more profitable?

Which has more risk & volatility, BCAB or PPBT?

Which has better earnings & valuation, BCAB or PPBT?

Do institutionals & insiders have more ownership in BCAB or PPBT?

Summary

How does Purple Biotech compare to Biorestorative Therapies?

Which has higher valuation and earnings, PPBT or BRTX?

Do analysts rate PPBT or BRTX?

Which has more volatility & risk, PPBT or BRTX?

Do insiders & institutionals hold more shares of PPBT or BRTX?

Is PPBT or BRTX more profitable?

Does the media refer more to PPBT or BRTX?

Summary

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools